Risk factors

Tvardi Therapeutics completed a reverse merger, shifting its risk profile entirely toward clinical development of TTI-101 and TTI-109.

Competition among SPACs may raise acquisition costs or prevent Twelve Seas III from completing a combination.

The company added specific disclosures on anti-takeover provisions and product-market alignment risks.

Nasdaq trading is suspended pending completion of a CSRC review, creating immediate liquidity and delisting risk.

Operating losses narrowed to $54.9 million in 2025, but servicing indebtedness remains costly.

Venu Holding Corp faces mounting risks regarding capital needs, construction delays, regulatory subpoenas, and share dilution.

The business faces severe disruption following the September 2025 termination of its preferred shipper relationship with its prior carrier partner.

Marketing and distribution support is now separately identified as a threat to product acceptance and revenue.

The Motiv merger adds major integration, retention, litigation, and cost risks while expected synergies may not materialize.

The risk section shifts away from bankrupt parent ETI issues toward operational execution in AI and workflow automation. New risks highlight long sales cycles, client contract termination terms, and competitive pressures in automation. Shareholder concentration risks update ownership figures for ETI, Gates Capital, and Avenue Capital.

Xsolla SPAC 1 completed a $200 million initial public offering on January 30, 2026, followed by a partial over-allotment exercise on February 2, 2026. Management has no prior operating revenue and relies on sponsor loans, with $270,009 in working capital deficit as of December 31, 2025. The company is focused on identifying an initial business combination, leveraging the video game and digital commerce expertise of its directors and executives.

Asset sales and reimbursement changes will lower 2026 revenue and gross margins.